The EPS beat of 26% vs consensus is largely mechanical given the tiny absolute base (-$0.57 vs -$0.77). The key catalyst is the randomized Phase 2 data for agenT-797 in ARDS expected H2 2026 — a binary event in a large unmet need market. Monitor cash runway closely; with $9.5M and quarterly burn of ~$3.9M, the company will likely need additional financing before year-end 2026. The ATS presentation on May 20 could provide a near-term catalyst if data is positive.
Price Chart
Executive Summary
MiNK Therapeutics reported Q1 2026 results with a net loss of $2.7M ($0.57 per share), beating consensus estimates of -$0.77 per share by 26%. The company advanced its lead iNKT cell therapy candidate agenT-797 into a randomized Phase 2 trial for acute lung injury, with preliminary data expected in H2 2026. Cash burn remains disciplined at $9.5M quarter-end, but the company continues to rely on at-the-market equity raises ($3.0M in Q1) and non-dilutive collaborations to fund operations.
Key Financial Metrics
Key Facts
- Net loss of $2.7M ($0.57 per share) vs $2.8M ($0.70 per share) in Q1 2025
- Cash and cash equivalents of $9.5M as of March 31, 2026, down from $13.4M at year-end 2025
- Repaid $5.2M Agenus convertible note during Q1 2026
- Raised $3.0M through at-the-market equity sales agreement in Q1 2026
- Initiated randomized Phase 2 trial for agenT-797 in severe acute lung injury/ARDS
- Preliminary Phase 2 data expected in second half of 2026
- Non-dilutive C-Further collaboration provides up to $1.1M for pediatric oncology program
- ATS conference presentation on agenT-797 in persistent infection scheduled for May 20, 2026
Financial Impact
Net loss improved slightly to $2.7M from $2.8M YoY; cash burn of ~$3.9M in Q1; $9.5M cash runway likely <12 months without additional financing
Risk Factors
- Cash runway of ~$9.5M may only fund operations through ~2-3 quarters without additional capital raises
- Phase 2 ARDS trial is early-stage with binary readout risk; no approved pharmacologic therapies exist in this indication
- Reliance on at-the-market equity sales for funding creates ongoing dilution for existing shareholders
- Clinical-stage biotech with no approved products or revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-225369 |
| Document: inkt-ex99_1.htm | 0001193125-26-225369 |
| Document: 0001193125-26-225369-index-headers.html | 0001193125-26-225369 |
| Document: 0001193125-26-225369-index.html | 0001193125-26-225369 |
| Document: 0001193125-26-225369.txt | 0001193125-26-225369 |
| 8-K Data (Synthetic) | 0001193125-26-225369 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 13, 2026 7w ago | Press Release | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 6, 2026 8w ago | Press Release | $11.00 $11.23 | ▲ +2.09% | ▲ +1.49% | $12.44 (+13.09%) |
May 28, 2026 18w ago | Press Release | $12.20 $11.64 | ▼ −4.59% | ▼ −1.45% | $12.44 (+1.97%) |
May 20, 2026 19w ago | Press Release | $10.72 $12.14 | ▲ +13.25% | ▲ +12.51% | $12.44 (+16.04%) |
May 15, 2026 20w ago | 8-K | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 15, 2026 20w ago | Press Release | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 14, 2026 20w ago | Press Release | $10.51 $12.02 | ▲ +14.37% | ▲ +15.23% | $12.44 (+18.36%) |
May 12, 2026 20w ago | Press Release | $11.41 $12.19 | ▲ +6.84% | ▲ +8.56% | $12.44 (+9.03%) |
May 8, 2026 20w ago | Press Release | $10.95 $11.82 | ▲ +7.95% | ▲ +8.25% | $12.44 (+13.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access